Dow Jones futures slip as Middle East tensions offset Fed rate cut hopes
Dow Jones futures inch lower by 0.07% to trade near 51,440 during European hours on Monday. S&P 500 futures decline by 0.09% to trade around 7,770, while Nasdaq 100 futures remain steady near 31,070.
US stock futures deliver mixed results as traders adopt a cautious stance amid surging safe-haven demand. This flight to safety was primarily driven by deteriorating geopolitical conditions in the Middle East, where tensions escalated sharply after Saudi-backed forces in Yemen launched a major offensive to reclaim territory from Houthi forces.
Middle East conflict intensified further following the Iran-aligned group's seizure of the Bab el-Mandeb strait, a critical maritime chokepoint linking the Red Sea to the Gulf of Aden that serves as a vital bypass route for regional crude exports avoiding the Strait of Hormuz.
Despite these geopolitical headwinds, broader market sentiment found underlying support as softer US jobs data eased pressure on the Federal Reserve to continue raising interest rates. Investors are now closely monitoring global risk sentiment while awaiting the release of the US ISM Services Purchasing Managers Index later in the day for clearer market direction. Corporate earnings are also taking center stage, with major releases expected from companies including Constellation Brands, Levi Strauss, PepsiCo, and Delta Air Lines.
US labour data seen resilient as Deutsche Bank still looks for further Fed hikes
Economists at Deutsche Bank acknowledge that the weaker September payrolls headline was underwhelming, but stress that “although the headline payroll number was disappointing, the wider labour-market picture remains relatively resilient, particularly alongside recent ADP and jobless-claims readings.” Against that backdrop, they note that their US team “continues to expect two further 25bp Fed hikes over the next couple of quarters,” arguing that the underlying labour-market signals remain consistent with a gradual extension of the current tightening cycle.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ecarx Completes Acquisition of Flyme Software Business
08:10 AM EDT, 10/05/2026 (MT Newswires) -- Ecarx (ECX) said Monday that it has closed its acquisition of the entire Flyme software business portfolio, including the Flyme Auto in-vehicle cockpit operating system and a cross-device Flyme operating system. The company said it paid 1.8 billion Chinese renminbi ($266 million) in cash, about 70% of which was funded by syndicated bank loans from Chinese commercial banks and roughly 30% from internal sources. After closing, Ecarx said it will provide the acquired business with 200 million renminbi to support its operations. Shares of Ecarx were up 5.8% pre-bell Monday.
BUZZ - US Stock Market Dynamics - RXO, Harley-Davidson, Vistra
Search string for querying individual stock trends in the workspace: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief" newsletter: https://refini.tv/3dKUyB8 Reuters, October 5 - On Monday, U.S. stock index futures edged lower as tech stocks retreated after reaching record highs. As Treasury yields and oil prices remain elevated, investors are seeking new clues about the direction of monetary policy. .N ** RXO RXO.N: Market focus — RXO shares rose following C.H. Robinson's announcement of a 5.8 billions USD acquisition plan nL6N45R0N4 ** Harley-Davidson HOG.N: Market focus — Citi upgraded Harley-Davidson to "Buy," shares climbed nL6N45R0M3 ** GEO Group GEO.N: Spotlight — GEO gained as it sold ICE facilities for 950 millions USD and expanded its stock buyback nL6N45R0MR ** Vistra VST.N: Spotlight — Vistra rallied as it was reportedly set to receive a 4.2 billions USD U.S. nuclear loan nL4N45R0L8 ** Vaxcyte PCVX.O: Spotlight — Vaxcyte surged after positive late-stage clinical trial data for its pneumococcal vaccine nL4N45R0K0 ** Estée Lauder EL.N: Spotlight — Barclays upgraded Estée Lauder to "Overweight," shares advanced nL6N45R0HX ** PTC PTC.O: Spotlight — Schneider Electric agreed to acquire PTC for 22.6 billions USD, shares jumped nL6N45R0HV (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translation may contain errors or fail to convey the required context, Reuters does not guarantee the accuracy of automatically translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)
BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug
October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)
Crypto prices
More
